Literature DB >> 3392371

Allergy to castor bean. I. Its relationship to sensitization to common inhalant allergens (atopy).

S C Thorpe1, D M Kemeny, R Panzani, M H Lessof.   

Abstract

The IgE response to castor bean (Ricinus communis) was studied in 96 castor bean-allergic patients from Marseilles, France. All had positive skin tests to castor bean. The IgE response to grass, cat, dust mite, olive, and Parietaria was also measured, and a positive RAST to one or more of these allergens was taken to indicate atopic status. Castor bean-specific IgE antibodies, measured by RAST, were found in 87 (91%) of the castor bean-allergic patients, in two of 13 atopic Marseilles residents living close to the castor bean mills, in three of 42 allergic subjects who had no known contact with castor bean, and in none of a control group of 111 Marseilles blood donors. Very high levels of castor bean-specific IgE (maximum class 4 readings on the Phadebas RAST score) were found in 54 (56%) of the castor bean-allergic patients, but the level of IgE antibody to castor bean was not significantly different in atopic and nonatopic subjects. The frequency of a positive serological test (RAST) for atopy in castor bean-allergic subjects (32%) was very similar to that found in the local population (36%). These data indicate that castor bean is an extremely potent sensitizer for both atopic and nonatopic individuals. The magnitude of the specific IgE antibody response is not related to the atopic status of the patient and may be a function of the physiochemical characteristics of the allergen itself.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392371     DOI: 10.1016/0091-6749(88)90052-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

1.  Factors relating to the development of respiratory symptoms in coffee process workers.

Authors:  K E Thomas; C J Trigg; P J Baxter; M Topping; J Lacey; B Crook; P Whitehead; J B Bennett; R J Davies
Journal:  Br J Ind Med       Date:  1991-05

2.  The contrasting effects of CD8+ T cells on primary, established and Nippostrongylus brasiliensis-induced IgE responses.

Authors:  B J Holmes; D Diaz-Sanchez; R A Lawrence; E B Bell; R M Maizels; D M Kemeny
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  The sensitivity of rat CD8+ and CD4+ T cells to ricin in vivo and in vitro and their relationship to IgE regulation.

Authors:  D Diaz-Sanchez; D M Kemeny
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

4.  Generation of a long-lived IgE response in high and low responder strains of rat by co-administration of ricin and antigen.

Authors:  D Diaz-Sanchez; D M Kemeny
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

5.  The effect of the castor bean toxin, ricin, on rat IgE and IgG responses.

Authors:  S C Thorpe; R D Murdoch; D M Kemeny
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

6.  IgE production, antigen-induced airway inflammation and airway hyperreactivity in the brown Norway rat: the effects of ricin.

Authors:  S L Underwood; D M Kemeny; T H Lee; D Raeburn; J A Karlsson
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  Ricin enhances IgE responses by inhibiting a subpopulation of early-activated IgE regulatory CD8+ T cells.

Authors:  D Diaz-Sanchez; T H Lee; D M Kemeny
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

8.  Innate responsiveness of CD8 memory T-cell populations nonspecifically inhibits allergic sensitization.

Authors:  Jamie A Leggat; Deena L Gibbons; Syeda F Y Haque; Adrian L Smith; James W Wells; Katherine Choy; Clare M Lloyd; Adrian C Hayday; Alistair Noble
Journal:  J Allergy Clin Immunol       Date:  2008-09-19       Impact factor: 10.793

9.  Identification of critical amino acids in the IgE epitopes of Ric c 1 and Ric c 3 and the application of glutamic acid as an IgE blocker.

Authors:  Natalia Deus-de-Oliveira; Shayany P Felix; Camila Carrielo-Gama; Keysson V Fernandes; Renato Augusto DaMatta; Olga L T Machado
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.